Insulet Reports Second-Quarter Revenue Growth as Full-Year U.S. Omnipod Outlook Is Lowered

{
  "signal_id": "24c5c62e-295d-fd5f-9af2-c1c5f8ceed8f",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-08-05T14:45:11+00:00",
  "company": {
    "name": "Insulet",
    "domain": "insulet.com"
  },
  "data": {
    "url": "https://finance.yahoo.com/healthcare/articles/insulet-reports-second-quarter-revenue-144511517.html",
    "title": "Insulet Reports Second-Quarter Revenue Growth as Full-Year U.S. Omnipod Outlook Is Lowered - finance.yahoo.com",
    "excerpt": "The diabetes device maker exceeded second-quarter revenue guidance but reduced its full-year U.S. Omnipod sales growth forecast as it continues scaling in the type 2 diabetes market. Insulet (NASDAQ:PODD) reported second-quarter revenue growth of 23.5% to $801.7 million, exceeding its guidance range. Omnipod revenue increased 24.6%, led by 35.5% international growth, while U.S. Omnipod revenue rose 20.1%. The company lowered its full-year U.S. Omnipod growth outlook to 17%-19% from 20%-22%, reducing total revenue guidance to 20%-22%. Adjusted operating margin improved by more than 140 basis points, while adjusted EPS increased 41.5% year over year. Insulet continued expanding the Omnipod platform through new international launches, product enhancements, and clinical data supporting future automated insulin delivery technologies. Insulet (NASDAQ:PODD) reported second-quarter 2026 revenue of $801.7 million, up 23.5% from a year earlier and above the high end of its constant-currency guidance. Total Omnipod revenue reached $795.9 million, with U.S. sales climbing 20.1% to $544.1 million and international revenue increasing 35.5% to $251.8 million. Profitability also strengthened despite continued investment in growth. Net income increased to $95.0 million, or $1.37 per diluted share, compared with $22.5 million, or $0.32 per diluted share, a year ago. Adjusted net income rose...",
    "product": "Omnipod 6",
    "summary": "Insulet is developing Omnipod 6 and a fully closed-loop insulin delivery technology for people with type 2 diabetes, supported by new clinical data.",
    "planning": true,
    "image_url": "https://s.yimg.com/lo/mysterio/api/3224B64E004A9E07BA15A8CB3027A48BD857D7C47E88683F734FCACE840DC5C3/subgraphmysterio/resizefill_w1200_h659;quality_80;format_webp/https:%2F%2Fmedia.zenfs.com%2Fen%2Finvestorshub_458%2Feb9737da2c9caa6ecd6572b4f453d3d6",
    "confidence": 0.9,
    "product_data": {
      "name": "Omnipod 6",
      "full_text": "Omnipod 6",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "future_tech"
    ],
    "published_at": "2026-08-05T14:45:11Z",
    "article_sentence": "Operationally, the company expanded Omnipod 5 into Spain, making it available in its 20th market, introduced a next-generation automated insulin delivery algorithm with broader sensor compatibility, and presented new clinical data supporting both Omnipod 6 and its fully closed-loop technology for people with type 2 diabetes."
  }
}

curl https://signals.autobound.ai/v1/signals/24c5c62e-295d-fd5f-9af2-c1c5f8ceed8f \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"insulet.com","limit":20}'